20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- The EMA said that European countries can begin to use Pfizer Inc's (NYSE:PFE) COVID-19 treatment pill Paxlovid, even though it is not yet authorized in the EU.
- The pill is indicated to treat adults with COVID-19 who do not require supplemental oxygen and are at increased risk of progressing to severe disease.
- Related Link: Final Data Reaffirms Efficacy Of Pfizer's COVID-19 Antiviral Treatment
- The early advice is based on clinical trial data from Pfizer showing 1% of patients (6 out of 607) who took Paxlovid within five days of the start of symptoms were hospitalized within 28 days of starting treatment compared with 6.7% of patients (41 out of 612) given a placebo.
- The FDA has yet to authorize Pfizer's pill.
- Price Action: PFE shares are up 3.71% at $61 during the market session on the last check Thursday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!